Abbott reported second-quarter 2026 adjusted diluted earnings per share (EPS) of $1.31 and raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60, up from a prior range of $5.38 to $5.58. Reported diluted EPS was $0.53. The company reaffirmed full-year comparable sales growth guidance of 6.5% to 7.5% and returned $2.1 billion to shareholders through dividends and share repurchases in the quarter.
Second-quarter sales rose 13.0% on a reported basis and 4.8% on a comparable basis. Worldwide Medical Devices sales increased 9.0% reported and 8.4% comparable, led by low-teens growth in electrophysiology and high single-digit growth in rhythm management, diabetes care, and heart failure. Continuous glucose monitor sales grew 11.0% reported and 9.5% comparable.
Established Pharmaceuticals sales grew 8.4% reported and 8.7% comparable, with key emerging markets posting 9.8% reported and 10.7% comparable growth, driven by double-digit gains in several Latin America and Asia Pacific countries. Worldwide Diagnostics sales increased 42.3% reported and 2.9% comparable, reflecting strong core lab growth in the U.S. and Latin America, lower respiratory testing volumes, and mid-teens growth for Cologuard in cancer diagnostics. Nutrition sales declined 3.1% reported and 3.6% comparable, though revenue rose $127 million sequentially versus the first quarter.
Operational highlights included completion of enrollment in the TECTONIC pivotal trial of its coronary intravascular lithotripsy system, new data in pulsed field ablation and conduction system pacing, CE Mark for the Libre Duo dual glucose–ketone sensor, FDA submission for the Amulet 360 LAA device, and updated colorectal cancer screening guidelines that continue to list Cologuard and Cologuard Plus as preferred options. Abbott projects third-quarter adjusted diluted EPS of $1.38 to $1.46.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!